The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. (Q54650775)

2 June 2018

title

The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. (English)

1 reference

2 June 2018

1 reference

1 reference

8

1 reference

2 June 2018

Tamer Abou Youssif

object named as

Tamer Abou Youssif

1

0 references

author name string

Mona Alam Fahmy

2

1 reference

2 June 2018

Ismael Herve Koumakpayi

3

1 reference

2 June 2018

Fernanda Ayala

4

1 reference

2 June 2018

Saeeda Al Marzooqi

5

1 reference

2 June 2018

Guangyong Chen

6

1 reference

2 June 2018

Pheroze Tamboli

7

1 reference

2 June 2018

Simon Tanguay

9

1 reference

2 June 2018

Kanishka Sircar

10

1 reference

2 June 2018

language of work or name

English

0 references

publication date

9 September 2010

1 reference

2 June 2018

published in

Cancer

1 reference

2 June 2018

volume

117

1 reference

2 June 2018

issue

2

1 reference

2 June 2018

page(s)

290-300

1 reference

2 June 2018

Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Activation of the mTOR signaling pathway in renal clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

The UCSC Genome Browser Database: 2008 update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Identification of new translocation breakpoints at 12q13 in lipomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Characterization of centromere alterations in liposarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Abnormalities in chromosome 17 and p53 in lung carcinoma cells detected by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

The Akt pathway in human breast cancer: a tissue-array-based analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25402

7 January 2021

Identifiers

DOI

10.1002/CNCR.25402

1 reference

2 June 2018

1 reference

2 June 2018